In early September, Oncology Venture AB and Medical Prognosis Institute (MPI) completed their strategic merger and the new entity, Oncology Venture A/S (OV), now trades on the NASDAQ First North Stockholm. Recently, OV’s three highest priority programmes all demonstrated progress. OV reported interim data from the LiPlaCis trial and is increasing enrolment, whereas 2X-121 received an IND from the US FDA in ovarian cancer. Furthermore, OV has a 55% stake in dovitinib, a tyrosine kinase inhibito...
Oncology Venture (OV) recently announced the initiation of its open-label Phase II study of 2X-121, a dual PARP-1/2 and TNKS-1/2 inhibitor, as a single agent in patients with metastatic breast cancer (mBC). The first patient, selected by OV’s 2X-121 drug response predictor (DRP) mRNA biomarker, was dosed in late June 2018. Also, OV announced that its impending merger with the Medical Prognosis Institute (MPI) will happen in September 2018. OV shareholders will own 51% of the new company.
Oncology Venture (OV) attended the annual American Society of Clinical Oncology (ASCO) in June with three abstracts. Results from a Phase I study of 2X-121, a dual PARP-1/2 and TNKS-1/2 inhibitor, as a single agent in patients with solid tumours were presented along with data on the development of the 2X-121 drug response predictor (DRP) algorithm. OV also provided supplementary data supporting the LiPlaCis and APO010 programmes at the conference. In late May, OV announced the merger between OV ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.